{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:19:48Z","timestamp":1788520788710,"version":"build-2803163510"},"reference-count":47,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare, debilitating autoimmune disease associated with pathogenic immunoglobulin G autoantibodies directed against components of the neuromuscular junction. The autoimmune nature of the disease and long-term immunosuppressive treatment may increase susceptibility to infections and malignancies, but studies investigating the association between MG and infections or malignancies remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, observational study using Optum's deidentified Market Clarity Data (Market Clarity) to evaluate the incidence rate (IR) of infections and malignancies in US-based patients with MG in a real-world setting. Adults with \u22652 diagnosis claims of MG were identified over a 2-year period (2016\u20132019) and propensity score (PS) matched with controls from the general population without MG. Patients with malignancies in the 1-year look-back period were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with MG (N\u2009=\u20095002) were compared with the PS-matched general population (N\u2009=\u200920,008). The IR of serious infections (primary outcome) was higher in the MG cohort compared with the general population (52.81 vs 31.46 per 1000 person-years [PY], respectively). IRs of opportunistic infections (87.48 vs 57.01 per 1000 PY) and infection-related death (3.98 vs 1.94 per 1000 PY) were also higher in the MG cohort compared with the general population. The overall rate of malignancy was higher in the MG cohort compared with the general population (73.55 vs 50.01 per 1000 PY, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this analysis, patients with MG were more susceptible to serious infections, infection-related death, and malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/22143602251403092","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T17:48:13Z","timestamp":1767808093000},"page":"898-908","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of infections and malignancy risks among patients with myasthenia gravis compared with matched controls in a US real-world setting"],"prefix":"10.1177","volume":"13","author":[{"given":"Jana","family":"Podhorna","sequence":"first","affiliation":[{"name":"argenx"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ward","sequence":"additional","affiliation":[{"name":"ZS Associates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-9228","authenticated-orcid":false,"given":"Kushal B.","family":"Naik","sequence":"additional","affiliation":[{"name":"ZS Associates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikjae","family":"Lee","sequence":"additional","affiliation":[{"name":"Columbia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4248-8927","authenticated-orcid":false,"given":"Yuebing","family":"Li","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ruhr University Bochum, BG University Hospital Bergmannsheil, Bochum, Germany"},{"name":"BG University Hospital Bergmannsheil, Heimer Institute for Muscle Research, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Teperov","sequence":"additional","affiliation":[{"name":"argenx"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[{"name":"argenx"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170294"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1339167"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14153"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12599"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00675"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26032"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1016728"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.17712\/1658-3183.2096"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241226745"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8751-9"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02448-4"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002024"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr333"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12108"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03621.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12383"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.11.007"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.07.060"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5091-9"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12329"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2021.03.015"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14730"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.11.006"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00525-x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0597-1"},{"key":"e_1_3_3_30_2","unstructured":"U.S. Food and Drug Administration. Framework for FDA\u2019s real-world evidence program. December 2018. https:\/\/www.fda.gov\/media\/120060\/download."},{"key":"e_1_3_3_31_2","unstructured":"Market Clarity Product Sheet. Accessed August 30 2024. https:\/\/www.optum.com\/content\/dam\/o4-dam\/resources\/pdfs\/sell-sheets\/mc-sell-sheet.pdf. 2024."},{"key":"e_1_3_3_32_2","unstructured":"US Department of Health and Human Services. Guidance regarding methods for de-identification of protected health information in accordance with the health insurance portability and accountability act (HIPAA) privacy rule. 26 November 2012. https:\/\/www.hhs.gov\/sites\/default\/files\/ocr\/privacy\/hipaa\/understanding\/coveredentities\/De-identification\/hhs_deid_guidance.pdf."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27526"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000521288"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207841"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1081\/SAC-200040691"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_3_38_2","doi-asserted-by":"crossref","unstructured":"Van Ness M Halpin-Gregorio R Bosschieter TM et al. The missing indicator method: from low to high dimensions. In: Proceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining Long Beach CA USA August 6\u201310 2023.","DOI":"10.1145\/3580305.3599911"},{"key":"e_1_3_3_39_2","unstructured":"World Health Organization (WHO). ICD-10 to MedDRA Mapping Conventions. June 2023. https:\/\/cdn.who.int\/media\/docs\/default-source\/classification\/icd\/icd-10\/icd-10-to-meddra-mapping-conventions.pdf?sfvrsn=1b36c13b_2#:\u223c:text=Mappings%20between%20ICD%2D10%20and checks%20for%20data%20consistency%2C%20routine."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.1252"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00391-011-0213-2"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(73)90033-6"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000551"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03667"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1801-y"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00004-6"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.08.040"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0160"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251403092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602251403092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251403092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:07:21Z","timestamp":1788520041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602251403092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/22143602251403092"],"URL":"https:\/\/doi.org\/10.1177\/22143602251403092","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}